Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Completed
- Conditions
- Anemia, Neoplasms
- Interventions
- Drug: epoetin beta [NeoRecormon]
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1060
- Registration Number
- NCT01168349
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
Terminated
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 734
- Registration Number
- NCT01168856
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
Phase 1
Completed
- Conditions
- Cytomegalovirus Infections, Heart Transplantation
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT01165580
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT01164891
A Study of RO5190591 (Danoprevir) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01164488
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01164007
- Locations
- 🇮🇹
Istituto Europeo Di Oncologia, Milano, Lombardia, Italy
A Study of RO5045337 in Patients With Solid Tumors
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT01164033
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 347
- Registration Number
- NCT01161173
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01159171
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01156961
© Copyright 2025. All Rights Reserved by MedPath